Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Chinese Journal of Biochemical Pharmaceutics ; (6): 215-217, 2017.
Artículo en Chino | WPRIM | ID: wpr-612751

RESUMEN

Objective To investigate the influence of ibuprofen and paracetamol on ductus arteriosus closure rate, laboratory parameters and complications risk of preterm infants with PDA.Methods110 preterm infants with PDA were chosen in July 2013 to July 2016 in iwu maternal and child health hospital and randomly divided into two groups.On the basis of conventional intervention, group A (55 cases) were treated with ibuprofen and group B (55 cases) were treated with paracetamol.The ductus arteriosus closure rate, the levels of PGE2, PLT, Cr and ALT before and after treatment and the complications incidence in the two groups were compared.ResultsThere was no significant difference of the ductus arteriosus closure rate between the two groups.The levels of PGE2 after treatment in the two groups were significantly lower than that before treatment(P<0.05).The levels of PGE2 after treatment in group B were significantly higher than that in group A(P<0.05).There was no significant difference of the levels of PLT, Cr and ALT before and after treatment between the two groups.The incidence of oliguresis in group B were significantly lower than that in group A(P<0.05).There was no significant difference of the incidence of positive fecal occult blood test, intraventricular hemorrhage, necrotizing enterocolitis and bronchopulmonary dysplasia between the two groups.ConclusionIbuprofen and paracetamol in the treatment of preterm infants with PDA possess the same effects in promote the arterial closure;Compared with ibuprofen, paracetamol application can efficiently reduce the oliguria risk and improve long-term prognosis.

2.
Chinese Journal of Epidemiology ; (12): 576-579, 2015.
Artículo en Chino | WPRIM | ID: wpr-240047

RESUMEN

<p><b>OBJECTIVE</b>To understand the one-year effect of HCV/HIV co-infected patients who had received AIDS second-line antiretroviral treatment after failure virologically, on the first-line therapy.</p><p><b>METHODS</b>HCV and HIV antibody positive patients who had experienced virological failure but received at least one-year AIDS first-line treatment, were recruited from May to October 2012 in Xincai, Queshan and Weishi of Henan province. 6-months and 12-months follow-up programs were carried out after the regimen had been changed to AIDS second-line antiretroviral treatment, CD4⁺ T lymphocyte count, HIV-1 virus load and HIV-1 drug resistance were performed.</p><p><b>RESULTS</b>Eighty-one cases of eligible patients were selected and followed by an amelioration of CD4 median at 6-month and 12-month follow-up period. Data showed that the baseline, 6-months and 12-months CD4 medians were 266 cells/µl, 275 cells/µl and 299 cells/µl (χ² = 8.214, P = 0.009). The ratio of HIV virus load suppression patients at 6-months and 12-months follow-up increased to 46.84% and 50.00%, respectively. Frequencies of HIV drug resistance also decreased at the baseline, 6-months and 12-months, with ratios as 66.67%, 26.58% and 27.63% (χ² = 29.362, P = 0.000), respectively. Ratios of patients that holding NRTI and NNRTI drug resistance appeared coinstantaneous decrease at the baseline, 6-months and 12-months, as 51.85%, 18.99% and 17.11% (χ² = 14.230, P = 0.005). At the baseline, the ratios of patients resisted to 3TC, ABC and FTC were all more than 50%, with AZT, D4T and DDI between 41%-44% while TDF appeared as 33.33%, then all of them declined to 12%-18% at the 6-month and 12-month follow-up periods. 65.43% of the patients resisted to both NVP and EFV but declined to 24%-27% at 6 months and 12 months.</p><p><b>CONCLUSION</b>HCV/HIV co-infected patients experienced virological failure of AIDS first-line therapy were ameliorated after changing to use second-line antiretroviral treatment for 6-months, but did not show constant positive effect at the 12-month end point.</p>


Asunto(s)
Humanos , Fármacos Anti-VIH , Farmacología , Usos Terapéuticos , Terapia Antirretroviral Altamente Activa , Linfocitos T CD4-Positivos , China , Coinfección , Farmacorresistencia Viral , Estudios de Seguimiento , Infecciones por VIH , Quimioterapia , VIH-1 , Hepatitis C , Quimioterapia , Inhibidores de la Transcriptasa Inversa , Farmacología , Usos Terapéuticos , Resultado del Tratamiento , Carga Viral
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA